These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

792 related items for PubMed ID: 15117984

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
    Perez EA, Suman VJ, Rowland KM, Ingle JN, Salim M, Loprinzi CL, Flynn PJ, Mailliard JA, Kardinal CG, Krook JE, Thrower AR, Visscher DW, Jenkins RB.
    Clin Breast Cancer; 2005 Dec; 6(5):425-32. PubMed ID: 16381626
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.
    Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R, Ghahramani P.
    J Clin Oncol; 2003 Nov 01; 21(21):3965-71. PubMed ID: 14507946
    [Abstract] [Full Text] [Related]

  • 5. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer.
    Gasparini G, Gion M, Mariani L, Papaldo P, Crivellari D, Filippelli G, Morabito A, Silingardi V, Torino F, Spada A, Zancan M, De Sio L, Caputo A, Cognetti F, Lambiase A, Amadori D.
    Breast Cancer Res Treat; 2007 Mar 01; 101(3):355-65. PubMed ID: 16850247
    [Abstract] [Full Text] [Related]

  • 6. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
    Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C.
    J Clin Oncol; 2008 Apr 01; 26(10):1642-9. PubMed ID: 18375893
    [Abstract] [Full Text] [Related]

  • 7. Prolonged administration of weekly paclitaxel and trastuzumab in patients with advanced breast cancer.
    Christodoulou C, Klouvas G, Pateli A, Mellou S, Sgouros J, Skarlos DV.
    Anticancer Res; 2003 Apr 01; 23(1B):737-44. PubMed ID: 12680177
    [Abstract] [Full Text] [Related]

  • 8. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.
    Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH, Eastern Cooperative Oncology Group Study 2598.
    J Clin Oncol; 2004 Apr 01; 22(7):1180-7. PubMed ID: 14981103
    [Abstract] [Full Text] [Related]

  • 9. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
    Ruiz M, Salvador J, Bayo J, Lomas M, Moreno A, Valero M, Bernabé R, Vicente D, Jiménez J, Lopez-Ladrón A.
    Cancer Chemother Pharmacol; 2008 Nov 01; 62(6):1085-90. PubMed ID: 18365200
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
    Yardley DA, Raefsky E, Castillo R, Lahiry A, Locicero R, Thompson D, Shastry M, Burris HA, Hainsworth JD.
    Clin Breast Cancer; 2011 Oct 01; 11(5):297-305. PubMed ID: 21729666
    [Abstract] [Full Text] [Related]

  • 12. Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
    Cortes J, Di Cosimo S, Climent MA, Cortés-Funes H, Lluch A, Gascón P, Mayordomo JI, Gil M, Benavides M, Cirera L, Ojeda B, Rodríguez CA, Trigo JM, Vazquez J, Regueiro P, Dorado JF, Baselga J, Spanish Breast Cancer Cooperative Group SOLTI.
    Clin Cancer Res; 2009 Jan 01; 15(1):307-14. PubMed ID: 19118059
    [Abstract] [Full Text] [Related]

  • 13. 4-years results of weekly trastuzumab and paclitaxel in the treatment of women with HER2/neu overexpressing advanced breast cancer: single institution prospective study.
    Janku F, Pribylova O, Zimovjanova M, Pazdrova G, Safanda M, Zemanova M, Petruzelka L.
    Bull Cancer; 2004 Oct 01; 91(10):E279-83. PubMed ID: 15582895
    [Abstract] [Full Text] [Related]

  • 14. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U, Wilke H, Seeber S.
    Semin Oncol; 1996 Oct 01; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [Abstract] [Full Text] [Related]

  • 15. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.
    Conlin AK, Seidman AD, Bach A, Lake D, Dickler M, D'Andrea G, Traina T, Danso M, Brufsky AM, Saleh M, Clawson A, Hudis CA.
    Clin Breast Cancer; 2010 Aug 01; 10(4):281-7. PubMed ID: 20705560
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
    Schaller G, Fuchs I, Gonsch T, Weber J, Kleine-Tebbe A, Klare P, Hindenburg HJ, Lakner V, Hinke A, Bangemann N.
    J Clin Oncol; 2007 Aug 01; 25(22):3246-50. PubMed ID: 17577021
    [Abstract] [Full Text] [Related]

  • 17. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
    De Maio E, Pacilio C, Gravina A, Morabito A, Di Rella F, Labonia V, Landi G, Nuzzo F, Rossi E, Silvestro P, Botti G, Di Bonito M, Curcio MP, Formichelli F, La Vecchia F, Staiano M, Maurea N, D'Aiuto G, D'Aiuto M, Thomas R, Signoriello G, Perrone F, de Matteis A.
    BMC Cancer; 2007 Mar 20; 7():50. PubMed ID: 17374151
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.
    Andre F, Campone M, O'Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA.
    J Clin Oncol; 2010 Dec 01; 28(34):5110-5. PubMed ID: 20975068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.